Savara Announces Resignation of Chief Medical Officer
August 26, 2022 08:05 AM Eastern Daylight Time AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical compa...
August 26, 2022 08:05 AM Eastern Daylight Time AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. 'We appreciate Dr. Chowdhury's contributions during his tenure with the company,' said Matt Pauls, Chair and CEO, Savara. 'His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future.